The artificial pancreas is a dream that is slowly coming true. In a new Insulin Nation article, author Martin Hensel reviews where we are and where we might be going with automated insulin dosing. To do that, he looks at the insulin dosing tools and the algorithms used within the hospital setting for insights on what future devices may hold.
The article features Monarch’s Executive Vice President and Chief Clinical Officer, Laurel Fuqua, RN, MSN, discussing EndoTool’s inpatient dosing algorithms and Ellie Strock, Vice President of US Medical Affairs at Voluntis, Monarch’s partner, discussing the outpatient movement.
Monarch Medical Technologies to Convene Industry Leaders in Inpatient Diabetes Management for Second Annual EndoTool® User Group Meeting
Healthcare Professionals from Leading Systems Gather to Share Best Practices Using EndoTool IV and EndoTool SubQ Across Hospital Units and Patient Populations.
Charlotte, N.C., October 9, 2018 – Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced that they will be hosting their annual EndoTool User Group Meeting on October 18th at the Ballantyne Hotel in Charlotte, NC. The event provides an opportunity for users of the EndoTool platform to share best practices, network with peers and discuss strategies to improve glycemic management across the continuum of care.
The agenda includes industry thought leaders across numerous organizations sharing change management strategies, industry trends in glucose management, and clinical results using EndoTool. read more…
New patent protects patient-specific methods and systems for safe subcutaneous and intravenous insulin dosing.
Charlotte, N.C., August 28, 2018 – Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced the U.S. Patent and Trademark Office (USPTO) has issued a new patent allowance, “Systems and Methods for Determining Insulin Therapy for a Patient.” The patent describes the unique methods and systems for more individualized insulin therapy in the inpatient setting, including accounting for the future insulin activity for intravenous and subcutaneous insulin therapy.
“This new patent covers aspects of our EndoTool® Glucose Management System, a Class II FDA-cleared software suite, providing patient-specific insulin dosing recommendations” said Linda Beneze, President and CEO of Monarch Medical Technologies. “Within the market, EndoTool is highly differentiated in its physiological approach to insulin dosing. We recognize the need to secure our intellectual property, which provides unique advantages that are best demonstrated in the improved clinical outcomes and associated cost reductions that our clients have experienced.” read more…
Dr. Carlos Mendez & Dr. Brian Ulmer Join Roster of Medical Experts to Support Company in Delivering Individualized Insulin Dosing for Improved Inpatient Diabetes Management
Charlotte, N.C., August 15, 2018 – Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced the appointments of Carlos Mendez, MD, FACP and Brian Ulmer, MD, CDE to Monarch’s Medical Advisory Board. The board serves to advise Monarch in the continual advancement of their services and solution, the EndoTool Glucose Management System, a Class II FDA-cleared, software suite, providing personalized dosing recommendations for intravenous and subcutaneous insulin therapy.
“We are pleased to welcome Dr. Mendez and Dr. Ulmer to our Medical Advisory Board,” said Laurel Fuqua, Executive Vice President and Chief Clinical Officer of Monarch Medical Technologies. “As recognized diabetes leaders with a wealth of experience as healthcare professionals and researchers, we are confident they will be invaluable as we continue to advance our predictive insulin dosing technology and glycemic management services in the ever-evolving and expanding market of glycemic management.” read more…
Monarch Medical Technologies and Voluntis Announce Partnership to Provide Seamless Solution for Insulin Dosing Across the Continuum of Care
Providers Can Bridge the Gap Between Inpatient and Outpatient Glycemic Management with Monarch’s EndoTool® Glucose Management System and Voluntis’ Insulia®
Cambridge, MA, and Charlotte, NC, June 20, 2018 – Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, and Voluntis (Euronext Paris: FRXX – VTX), a company specialized in digital therapeutics, today announced a new strategic partnership aimed at improving the coordination of glycemic management for patients with insulin dosing recommendations in both the inpatient and outpatient setting.
Monarch is the developer of the EndoTool Glucose Management System, an FDA-cleared software suite, providing safe, individualized, and precise inpatient insulin dosing recommendations through its two applications, EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin therapy.
Voluntis’ Insulia is an FDA-cleared, prescription-only digital therapeutic for people and their care teams using basal insulin to treat type 2 diabetes. Insulia provides automated basal insulin dose recommendations and personalized coaching messages, while enabling the health care team to remotely monitor progress.
In the U.S., 7.2 million of the total 30.3 million individuals with diabetes are undiagnosed, and many first find out about their diagnosis and initiate insulin treatment while in the hospital. These patients can feel lost when transitioning from the highly-regimented inpatient hospital setting to being on their own in an outpatient setting. The objective in combining the power of these two systems is to take patients from successful insulin dosing in the hospital, using the EndoTool Glucose Management System, to continued effective insulin treatment at home, using Insulia for daily follow-up. read more…
Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced that it has been selected by Modern Healthcare as one of the 2018 Best Places to Work in Healthcare. This is the second year that Monarch has received the award.
“At Monarch, our motto is, ‘Never Satisfied. Always Evolving.’ We are not satisfied with the status quo, and we will continue to evolve to improve the safety of insulin delivery and advance patient care,” said Linda Beneze, President and CEO, Monarch Medical Technologies. “We are honored to be recognized as one of Modern Healthcare’s Best Places to Work in Healthcare. This award is a testament to our team who truly live by this motto each day through their hard work and unwavering commitment to our clients and one another.”
The annual award program identifies and recognizes outstanding employers in the healthcare industry nationwide. Monarch was one of the 150 companies and organizations around the country selected for the award and was one of four organizations selected from the state of North Carolina. read more…
Presenter Jane Jeffrie Seley, Program Manager of the Inpatient Glycemic Control Program at NewYork-Presbyterian Hospital/Weill Cornell Medicine, to Focus on Strategies to Engage Nursing Staff in Glycemic Management Practices.
Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced that the company will host a complimentary educational webinar, “The Role of Nursing in the Continuum of Inpatient Diabetes Care,” on May 23, from 1-2 p.m. EDT.
During this webinar, Jane Jeffrie Seley, DNP, MSN, MPH, GNP, RN, BC-ADM, CDE, CDTC, FAADE, FAAN, Program Manager of the Inpatient Glycemic Control Program at NewYork-Presbyterian Hospital/Weill Cornell Medicine, will present on the elements of effective glycemic management requiring nursing coordination of care and best practice to engage your nursing staff. Following the presentation, Dr. Seley will be joined by Travis Scott, Nurse Educator at Oregon Health & Science University and Laurel Fuqua, Monarch’s EVP and Chief Clinical Officer, for a panel discussion sharing experiences and successful examples of improving engagement, care coordination, and staff education to optimize diabetes care and improve patient outcomes.
In the April ACP Hospitalist article, “Taking glucose management online,” author Janet Colwell discusses how new algorithms and virtual systems are being used to help hospitals optimize their inpatient glycemic control.
The author notes that while recommended glucose targets remain elusive for many hospitals, some institutions have made inroads by leveraging the power of computerized systems to optimize insulin dosing, including Vidant Medical Center in Greenville, N.C., which uses EndoTool. Robert Tanenberg, MD, MACP, professor of medicine at East Carolina University and medical director of the inpatient diabetes program at Vidant, discussed how by using EndoTool, they have “achieved better overall control and almost zero hypoglycemia—in less time.”
Monarch’s Laurel Fuqua Authors Article, “Taking flight: Adopting technology to improve inpatient glycemic management”
In a new Becker’s Health IT & CIO Review article, “Taking flight: Adopting technology to improve inpatient glycemic management,” Monarch’s EVP and Chief Clinical Officer, Laurel Fuqua, compares the airlines industry to healthcare when it comes to safety. The safety of flying dramatically improved over the past 50 years because of the introduction of new technology and protocols. In comparison, hospital medical errors continue to remain one of the leading causes of death in the United States.
While healthcare has certainly benefited from the introduction of technology and new methods, adoption of such advancements doesn’t happen nearly as quickly as it should, and how we dose insulin in the inpatient setting is a prime example. In the article, Laurel describes the need to take advantage of a more advanced approach to insulin dosing utilizing an electronic glucose management system.
Monarch Medical Technologies Announces Self-Service Analytics, An Expansion of the EndoTool® Analytics Offering
Self-Service Analytics Expands on Current EndoTool Analytics Offering Allowing Clients to Utilize Existing Business Intelligence Tools for Advanced Data Mining
Monarch Medical Technologies, the leader in precision insulin dosing for optimized inpatient glucose management, today announced the launch of Self-Service Analytics, an extension of EndoTool Analytics. The new Self-Service Analytics module enables hospitals using EndoTool IV for patients on IV insulin and/or EndoTool SubQ for patients requiring insulin via injections to further mine patient data and identify larger trends in their clinical outcomes and processes using their existing analytics tools and infrastructure.
EndoTool Self-Service Analytics allows users to generate standard reports from a pre-built data warehouse using business intelligence tools, such as Tableau and MicroStrategy, or direct query. The EndoTool data warehouse will pre-aggregate data for key metrics allowing clients to build reports that provide a holistic view of patient and clinician performance using EndoTool across the organization.